174 related articles for article (PubMed ID: 34680394)
1. The Oncogene
Sradhanjali S; Rout P; Tripathy D; Kaliki S; Rath S; Modak R; Mittal R; Chowdary TK; Reddy MM
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680394
[TBL] [Abstract][Full Text] [Related]
2. Aurora Kinase B Expression, Its Regulation and Therapeutic Targeting in Human Retinoblastoma.
Borah NA; Sradhanjali S; Barik MR; Jha A; Tripathy D; Kaliki S; Rath S; Raghav SK; Patnaik S; Mittal R; Reddy MM
Invest Ophthalmol Vis Sci; 2021 Mar; 62(3):16. PubMed ID: 33704359
[TBL] [Abstract][Full Text] [Related]
3. Aurora kinase A is overexpressed in human retinoblastoma and correlates with histopathological high-risk factors: implications for targeted therapy.
Borah NA; Mittal R; Sucharita S; Rath S; Kaliki S; Patnaik S; Tripathy D; Reddy MM
Am J Pathol; 2024 Jun; ():. PubMed ID: 38879085
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of pRb: mechanism for RB pathway inactivation in MYCN-amplified retinoblastoma.
Ewens KG; Bhatti TR; Moran KA; Richards-Yutz J; Shields CL; Eagle RC; Ganguly A
Cancer Med; 2017 Mar; 6(3):619-630. PubMed ID: 28211617
[TBL] [Abstract][Full Text] [Related]
5. Silencing of the Long Noncoding RNA MYCNOS1 Suppresses Activity of MYCN-Amplified Retinoblastoma Without RB1 Mutation.
Saengwimol D; Chittavanich P; Laosillapacharoen N; Srimongkol A; Chaitankar V; Rojanaporn D; Aroonroch R; Suktitipat B; Saisawang C; Svasti S; Hongeng S; Kaewkhaw R
Invest Ophthalmol Vis Sci; 2020 Dec; 61(14):8. PubMed ID: 33270844
[TBL] [Abstract][Full Text] [Related]
6. Effect of CDK7 inhibitor on MYCN-amplified retinoblastoma.
Xu H; Xiao L; Chen Y; Liu Y; Zhang Y; Gao Y; Man S; Yan N; Zhang M
Biochim Biophys Acta Gene Regul Mech; 2023 Sep; 1866(3):194964. PubMed ID: 37536559
[TBL] [Abstract][Full Text] [Related]
7. Retinoblastoma with MYCN Amplification Diagnosed from Cell-Free DNA in the Aqueous Humor.
Joseph S; Pike S; Peng CC; Brown B; Xu L; Berry JL; Chévez-Barrios P; Hubbard GB; Grossniklaus HE
Ocul Oncol Pathol; 2024 Apr; 10(1):15-24. PubMed ID: 38751495
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of pyruvate dehydrogenase kinase 1 in retinoblastoma: A potential therapeutic opportunity for targeting vitreous seeds and hypoxic regions.
Sradhanjali S; Tripathy D; Rath S; Mittal R; Reddy MM
PLoS One; 2017; 12(5):e0177744. PubMed ID: 28505181
[TBL] [Abstract][Full Text] [Related]
9. Role of MYCN in retinoblastoma: A review of current literature.
Vempuluru VS; Maniar A; Bakal K; Kaliki S
Surv Ophthalmol; 2024 May; ():. PubMed ID: 38796108
[TBL] [Abstract][Full Text] [Related]
10. A mouse model of MYCN-driven retinoblastoma reveals MYCN-independent tumor reemergence.
Wu N; Jia D; Bates B; Basom R; Eberhart CG; MacPherson D
J Clin Invest; 2017 Mar; 127(3):888-898. PubMed ID: 28165337
[TBL] [Abstract][Full Text] [Related]
11. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells.
Wallick CJ; Gamper I; Thorne M; Feith DJ; Takasaki KY; Wilson SM; Seki JA; Pegg AE; Byus CV; Bachmann AS
Oncogene; 2005 Aug; 24(36):5606-18. PubMed ID: 16007177
[TBL] [Abstract][Full Text] [Related]
12. High-Level
Roohollahi K; de Jong Y; van Mil SE; Fabius AWM; Moll AC; Dorsman JC
Ophthalmol Sci; 2022 Sep; 2(3):100188. PubMed ID: 36245757
[TBL] [Abstract][Full Text] [Related]
13. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.
Rushlow DE; Mol BM; Kennett JY; Yee S; Pajovic S; Thériault BL; Prigoda-Lee NL; Spencer C; Dimaras H; Corson TW; Pang R; Massey C; Godbout R; Jiang Z; Zacksenhaus E; Paton K; Moll AC; Houdayer C; Raizis A; Halliday W; Lam WL; Boutros PC; Lohmann D; Dorsman JC; Gallie BL
Lancet Oncol; 2013 Apr; 14(4):327-34. PubMed ID: 23498719
[TBL] [Abstract][Full Text] [Related]
14. Global gene deregulations in FASN silenced retinoblastoma cancer cells: molecular and clinico-pathological correlations.
Sangeetha M; Deepa PR; Rishi P; Khetan V; Krishnakumar S
J Cell Biochem; 2015 Nov; 116(11):2676-94. PubMed ID: 25958981
[TBL] [Abstract][Full Text] [Related]
15. Functional genomics identifies new synergistic therapies for retinoblastoma.
Aubry A; Pearson JD; Huang K; Livne-Bar I; Ahmad M; Jagadeesan M; Khetan V; Ketela T; Brown KR; Yu T; Lu S; Wrana JL; Moffat J; Bremner R
Oncogene; 2020 Jul; 39(31):5338-5357. PubMed ID: 32572160
[TBL] [Abstract][Full Text] [Related]
16. Identification and pharmacological inactivation of the MYCN gene network as a therapeutic strategy for neuroblastic tumor cells.
Chayka O; D'Acunto CW; Middleton O; Arab M; Sala A
J Biol Chem; 2015 Jan; 290(4):2198-212. PubMed ID: 25477524
[TBL] [Abstract][Full Text] [Related]
17. Profiling genomic copy number changes in retinoblastoma beyond loss of RB1.
Bowles E; Corson TW; Bayani J; Squire JA; Wong N; Lai PB; Gallie BL
Genes Chromosomes Cancer; 2007 Feb; 46(2):118-29. PubMed ID: 17099872
[TBL] [Abstract][Full Text] [Related]
18. Rb suppresses human cone-precursor-derived retinoblastoma tumours.
Xu XL; Singh HP; Wang L; Qi DL; Poulos BK; Abramson DH; Jhanwar SC; Cobrinik D
Nature; 2014 Oct; 514(7522):385-8. PubMed ID: 25252974
[TBL] [Abstract][Full Text] [Related]
19. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
20. Co-deleting Pten with Rb in retinal progenitor cells in mice results in fully penetrant bilateral retinoblastomas.
Xie C; Lu H; Nomura A; Hanse EA; Forster CL; Parker JB; Linden MA; Karasch C; Hallstrom TC
Mol Cancer; 2015 Apr; 14():93. PubMed ID: 25907958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
